Doris Mayer1, Ernst Chantelau. 1. Hormones and Signal Transduction Group, German Cancer Research Centre, DKFZ-ZMBH Alliance, Im Neuenheimer Feld 581, Heidelberg, Germany. d.mayer@dkfz.de
Abstract
CONTEXT AND OBJECTIVE: Insulin glargine (Lantus) stimulates growth of MCF-7 cells stronger than human insulin. We investigated if serum from diabetic patients treated with glargine versus human insulin may display a similar effect. METHODS: Pairs of serum samples from 31 C-peptide negative type-1 diabetic patients were investigated. In cross-over fashion, 23 patients were treated with glargine plus rapid-acting insulin analogues, and similar doses of human NPH and rapid-acting insulin. For comparison, eight patients were treated with insulin detemir (Levemir) and human NPH. MCF-7 cells were incubated with 10% serum and proliferation was assessed after 72 hours. RESULTS: Serum containing insulin glargine was 1.11(95% CI 1.05-1.18) fold more mitogenic than human insulin-containing serum (p < 0.005); mitogenicity of serum containing detemir was 0.99(95% CI 0.98-1.02) fold that of human insulin-containing serum. CONCLUSION: The serum of diabetic patients was slightly stronger mitogenic when using glargine as compared to human insulin or detemir for treatment.
CONTEXT AND OBJECTIVE:Insulin glargine (Lantus) stimulates growth of MCF-7 cells stronger than humaninsulin. We investigated if serum from diabeticpatients treated with glargine versus humaninsulin may display a similar effect. METHODS: Pairs of serum samples from 31 C-peptide negative type-1 diabeticpatients were investigated. In cross-over fashion, 23 patients were treated with glargine plus rapid-acting insulin analogues, and similar doses of human NPH and rapid-acting insulin. For comparison, eight patients were treated with insulindetemir (Levemir) and human NPH. MCF-7 cells were incubated with 10% serum and proliferation was assessed after 72 hours. RESULTS: Serum containing insulin glargine was 1.11(95% CI 1.05-1.18) fold more mitogenic than humaninsulin-containing serum (p < 0.005); mitogenicity of serum containing detemir was 0.99(95% CI 0.98-1.02) fold that of humaninsulin-containing serum. CONCLUSION: The serum of diabeticpatients was slightly stronger mitogenic when using glargine as compared to humaninsulin or detemir for treatment.
Authors: Artur Matyszewski; Anna Czarnecka; Maciej Kawecki; Piotr Korzeń; Ilan J Safir; Wojciech Kukwa; Cezary Szczylik Journal: Oncol Lett Date: 2015-06-04 Impact factor: 2.967
Authors: Vinay Bhaskar; Ira D Goldfine; Daniel H Bedinger; Angela Lau; Hua F Kuan; Lisa M Gross; Masahisa Handa; Betty A Maddux; Susan R Watson; Shirley Zhu; Ajay J Narasimha; Raphael Levy; Lynn Webster; Sujeewa D Wijesuriya; Naichi Liu; Xiaorong Wu; David Chemla-Vogel; Catarina Tran; Steve R Lee; Steve Wong; Diane Wilcock; Mark L White; John A Corbin Journal: Diabetes Date: 2012-03-08 Impact factor: 9.461
Authors: A J Varewijck; J A M J L Janssen; M Vähätalo; L J Hofland; S W J Lamberts; H Yki-Järvinen Journal: Diabetologia Date: 2012-01-10 Impact factor: 10.122